Cathyy's Debates: [clear]
All Debates
You are browsing through all debates. You can refine the results by using the drop-down boxes above. You can view more information about each debate by clicking Show Details at right.
Winning Position: Unresolved
Why Should I Conduct Stress Related Behavior TestsIndividuals respond differently to stress, and there are significant individual differences in stress response values.The study of individual differences in response to stress and the neurobiological mechanisms involved is essential for understanding, diagnosing and treating stress-related disorders.The establishment of stress models is critical to the reliability and accuracy of experimental results.
Winning Position: Unresolved
Local toxicity evaluation is used to study the toxic reactions caused by topical administration and is an important part of toxicology studies. Our company offers comprehensive services and technical support covering every stage of preclinical rare disease therapy research and development, designed to help our clients address possible barriers and challenges in local toxicity evaluation for rare diseases.
Winning Position: Unresolved
Learning and memory are important functions and activities of the nervous system that are interconnected with each other. With the rapid development of neuroscience, behavioral science has been an essential tool to study learning and memory related disorders.Our company has a professional animal behavior testing and data analysis platform, and is committed to providing high quality learning and memory behavior testing services to universities and research Institutes.Learn more:Learning and Memory Tests
Winning Position: Unresolved
General toxicity evaluation can enable researchers to understand the toxic mechanism of rare disease drugs on the body and provide a basis for clinical research. Our company is a CRO with many years of experience in toxicology evaluation. Experts with high-level and professional knowledge backgrounds can provide you with comprehensive and high-quality services to meet all your requirements for general toxicity evaluation in rare disease drug and therapy research.What is General Toxicology Evaluation?General toxicity evaluation refers to the ability of a drug to produce an overall toxic effect on the experimental animal body at a certain dose, a certain contact time, and a certain contact method. General toxicity evaluation is the basis for safety assessment and is crucial for drug efficacy research. General toxicity evaluation includes acute, sub-acute, sub-chronic, and chronic toxicity evaluation.Learn more:Toxicology Evaluation
Winning Position: Unresolved
In recent years, as advances in technology have revealed new uses for artificial intelligence, it is increasingly being applied to the study of a wide range of diseases, including rare diseases. Our company is committed to providing customers with artificial intelligence services to help predict, study and identify rare diseases and develop treatments.Learn more:Artificial Intelligence in Medicine
Winning Position: Unresolved
Evaluation of Antipsychotic DrugsCurrent Status of Development of Drugs for Psychiatric DisordersHuge market demandWith the increase of people's social pressure, the number of patients is increasing year by year, and the search for efficient and safe antipsychotic drugs has become more than a dozen urgent.Strong dependence of patients on drugsPsychiatric disorders are often difficult to cure, and patients are highly dependent on medications, often requiring long-term or even lifelong medication to relieve symptoms.Large space for drug developmentFew drugs with significant breakthrough therapeutic effects have been reported, and existing therapeutic drugs have limited their use and efficacy due to safety and drug resistance issues. Therefore, there is great space for the development of drugs for psychiatric disorders.
Winning Position: Unresolved
To date, viral and non-viral vectors have been widely used as two common strategies for delivering genes of interest to multiple target tissues, and they have been successfully used to treat a variety of genetic diseases such as cystic fibrosis, Leber's congenital amaurosis, and various severe combined immunodeficiency (SCID). Viral vectors are highly efficient at transducing genes but are immunogenic. Non-viral vectors have lower transfection efficiency, but they are generally less immunogenic. Both types of vectors have advantages and disadvantages that hinder their therapeutic endpoints in clinical trials.To take advantage of the strengths of both types of vectors, researchers have attempted to develop hybrid vector combinations of viral and chemical vectors to achieve higher gene delivery efficiency than individual vectors alone. These hybrid vectors overcome the limitations associated with both delivery systems while enhancing desired features such as low immunogenicity, targeting ability, higher payload, and the ability to deliver multiple transgenes, thus making gene therapy a clinically available technology.
Winning Position: Unresolved
Drug development for rare diseases is faced with the dilemma of a small number of patients, scarcity of research samples, and high difficulty of clinical trials. One of the major problems hindering drug development for rare diseases is the lack of suitable animal models in preclinical studies. The establishment and availability of stable and reliable animal models of rare diseases are irreplaceable for the study of rare diseases. They have an inestimable potential for the study of rare disease pathogenesis, drug target research, and therapeutic effects evaluation. Several excellent models have already been developed, such as the GAA-knockout mouse model for Pompe's disease and the Sgca-null mouse model for α-sarcoglycanopathy. Some of these have already led to the development of much-needed therapies such as ERTs. Nevertheless, there is a continuing need to develop more effective models to facilitate drug development and clinical trial design for rare diseases.Fig. 1 Animal models presented to the EMA Committee for Orphan Medicinal Products. (Vaquer G, et al., 2013)
Winning Position: Unresolved
The device for the treadmill test consists mainly of a rolling conveyor belt. The rear wall of the conveyor belt is equipped with stimulation electrodes and sound generating devices, and the stimulation devices of each channel are independent of each other. During the test, the rodents did running exercise training on a running platform with a set speed. If the animal refuses to move or moves at a speed lower than the experimental speed it will backtrack on the track and touch the stimulation device. Stronger electrical or acoustic stimuli will force the experimental animal to move at the speed of the running platform.Fig. 1 Treadmill test in mice.Experimental FlowOur company is committed to providing customized testing processes to meet all of our customers' demands in relevant research.Pre-lab preparation and animal grouping.Before formal training, the animals are released to the track for a period of acclimatization.Place the experimental animals in the corresponding runway according to the number, and set the parameters such as the time, speed, and shock intensity of the treadmill.Record the corresponding parameter indicators during the training of experimental animals.
Winning Position: Unresolved
The process of repurposing drugs for new indications is a time- and cost-efficient approach with a higher success rate than developing new orphan drugs, thus significantly reducing the risk of drug development for rare diseases. Our company has an integrated technology platform to offer customers drug repositioning services and screening services of these compounds for new therapeutic purposes, accelerating the development of new therapies for rare diseases.Drug Repurposing Screening for Rare DiseasesThere are approximately 7,000 identified rare and neglected diseases, the vast majority of which lack effective treatments. The development of new treatments for rare diseases is a major challenge because the drug discovery process is often laborious, expensive, and prone to failure, it is particularly unappealing for rare diseases that affect only a small number of people and thus generate reduced profits. Drug repurposing has been proposed as an alternative strategy for the development of new therapies, particularly in the field of rare diseases. It offers lower risks, lower costs, and shorter timescales than the development of novel orphan drugs.Drug repurposing, also known as drug repositioning or drug reprofiling, is the process of redeveloping compounds for use in different diseases. The strategy is based on the scientific principles that a single drug often interacts with multiple targets or pathways, and multiple drugs may act on the same target or pathway. With the Human Genome Project providing a wealth of genetic information on many rare diseases, including gene regulation, protein structure, and drug-target interactions, scientists have the opportunity to make breakthrough achievements in the field of drug repurposing.
Winning Position: Unresolved
Overview of Drug Safety EvaluationNew types of drugs and new preparations are constantly emerging, and various safety issues are also arising. The purpose of drug safety evaluation is to determine the safe amounts and timing of drugs to avoid the occurrence of adverse events. Drug safety evaluation is a necessary procedure and an important step before new drugs enter final clinical trials and final approval. Traditional drug safety evaluation technologies and methods can no longer meet the growing needs. Research focuses on finding and establishing fast and accurate drug safety evaluation technologies and methods.Genetic Toxicology EvaluationChromosomal Aberration AssayMicrowell Micronucleus AssayBacterial Mutation AssSub-acute Toxicity EvaluationDevelopmental and Reproductive Toxicity EvaluationFertility and Early Embryo Development ToxicityEmbryo-fetal Development ToxicityPerinatal Toxicity